SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

NCT03645876 | Terminated Phase 2

• 1 other identifier: SHR-1210-II-210
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC. SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a humanized recombinant monoclonal IgG1 antibody. The primary objective of this study is to investigate the safety and efficacy of the subjects who given the combination therapy.

Conditions

Metastatic Colorectal Cancer

Keywords

SHR-1210; BP102; Phase II

Outcome Measures

Primary Outcomes (2)

• Safety of the combination therapy: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

  From sign icf to the end of follow-up

  24 months

• Objective response rate

  From sign icf to occurrence of objective response (complete regression (CR) and partial regression (PR) need to be confirmed 28 days after the occurrence)

  24 months

Secondary Outcomes (5)

• DOR

  24 months

• DCR

  24 months

• PFS

  24 months

• 9month PFS rate

  9 months

• 12month and 24 month OS rate

  24 months

Other Outcomes (1)

• Biomarkers and ADA

  24 months

Study Arms (1)

SHR-1210+BP102+XELOX

EXPERIMENTAL

Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity

Drug: SHR-1210; Drug: BP102; Drug: oxaliplatin; Drug: capecitabine

Interventions

SHR-1210 DRUG

200mg

SHR-1210+BP102+XELOX

BP102 DRUG

7.5mg/kg

SHR-1210+BP102+XELOX

oxaliplatin DRUG

130mg/m2

SHR-1210+BP102+XELOX

capecitabine DRUG

1000mg/m2

SHR-1210+BP102+XELOX

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 and ≤75 years old;
• Histologically confirmed colorectal cancer with a metastatic / recurrent lesion that cannot be cured by surgery.
• At least one measurable lesion have been the confirmatory detection respect to RECIST 1.1
• No prior first-line systemic anti-tumor therapy for mCRC (including systemic chemotherapy, molecular targeted therapy, biotherapy, immunotherapy, radiotherapy, local therapy and other study treatment) have been identified
• At least 6 months have elapsed if considering the interval from the time of firstly documented metastasis to the post-operational adjuvant chemotherapy termination
• Can provide either a newly obtained or archival tumor tissue sample.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Life expectancy ≥ 3 months
• Subjects must have normal organ and marrow function as defined below:
• Absolute neutrophil count (ANC) ≥1,500 /mm3（1.5×109 /L）
• Platelets ≥90,000 / mm3（90×109 /L）
• Hemoglobin ≥10 g/dL, within the 2 weeks prior to the screening no need for the transfusion
• Serum albumin ≥2.8 g/dL
• Total bilirubin≤ 1.5 X ULN, AST (SGOT), ALT (SGPT) ≤ 2.5 X ULN (AST/ALT ≤ 5 X ULN if liver metastatic);
• Creatinine clearance ≥ 50 mL/min according to Cockcroft-Gault formula

You may not qualify if:

• Prior first-line systemic anti-tumor therapy for mCRC (including systemic chemotherapy, molecular targeted therapy, immunotherapy, biotherapy, and other treatment).
• The metastatic/recurrent lesion is subject to be cured by surgical intervention.
• Major operation or open biopsy or major trauma within 4 weeks prior to first dose.
• Known Cerebral and/or leptomeningeal metastasis.
• Bleeding predisposition, high bleeding risk or coagulant disorder, thrombotic event(s) occurrence ≤6 months and/or hemoptysis ≤3 months (≥ 1/2 teaspoons fresh blood each) prior to the screening; use of full dose oral or parenteral anticoagulant or thrombolytic medication (allowing preventative anticoagulation); use of aspirin (\> 325 mg/day) or other platelet-inhibition non-steroidal anti-inflammatory drugs within 10 days since the screening; CT/MRI imaging evidence, testimony of the main arteries/veins (such as pulmonary artery or superior vena cava) being infringed, encroached
• Subjects with uncontrolled hypertension and with a medical history of hypertensive crisis or hypertensive encephalopathy; serious cardiovascular and cerebrovascular diseases, including cerebrovascular accident (CVA) ≤6 months before the screening, transient ischemic attack (TIA), myocardial infarction and significant vascular disease (including but not limited to aortic aneurysms with need for surgical repair or recent evidence of arterial thrombosis), unstable angina, heart failure and serious arrhythmias that are uncontrolled by drugs (New York Heart Association Class ≥2).
• Subjects with non-healing wounds, active peptic ulcer or fracture and active infection; tracheal esophageal fistula, gastrointestinal perforation or gastrointestinal fistula and abdominal abscess in the 6 months prior to the screening.
• Subjects with any active autoimmune disease or history of autoimmune disease
• Active infection or an unexplained fever \> 38.5°C before two weeks of randomization (subjects with tumor fever may be enrolled at the discretion of the investigator);
• History of Interstitial Pneumonia or received Corticosteroids for non-infectious pneumonitis.
• Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C.
• Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR-1210 or BP102 formulation, allergy, hypersensitivity, or contraindication to oxaliplatin, or Capecitabine
• Currently participating or has participated in a study within 4 weeks of the first dose of study medication.
• Has a known additional malignancy within the last 5 years before study treatment with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers
• Received a live vaccine within 4 weeks of the first dose of study medication

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Cancer Center of Sun-Yat Sen University (CCSYSU)

Guangzhou, Guangdong, 510060, China

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

camrelizumab; Oxaliplatin; Capecitabine

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 20, 2018
• First Posted: August 24, 2018
• Study Start: November 8, 2018
• Primary Completion: April 18, 2019
• Study Completion: April 18, 2019
• Last Updated: May 10, 2019

Record last verified: 2019-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)